| Mrs Amanda Kay Douma, APNP | |
|
333 N Green Bay Rd Ste B, Neenah, WI 54956-1954 | |
| (920) 454-7130 | |
| Not Available |
| Full Name | Mrs Amanda Kay Douma |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 333 N Green Bay Rd Ste B, Neenah, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043697048 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 6264 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Agnes Hospital | Fond du lac, WI | Hospital |
| Waupun Memorial Hospital | Waupun, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Agnesian Healthcare Inc | 1658289624 | 319 |
News Archive
An opinion article aims to provide evidence that SP could be the possible factor for initiating the cytokine storm during severe SARS-CoV-2 infection.
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.
Ten years ago, a landmark clinical trial in Canada demonstrated the unequivocal effectiveness of brain surgeries for treating uncontrolled epilepsy, but since then the procedure has not been widely adopted-in fact, it is dramatically underutilized according to a new study from the University of California, San Francisco (UCSF).
› Verified 5 days ago
| Entity Name | Agnesian Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346228541 PECOS PAC ID: 1658289624 Enrollment ID: O20031104000263 |
News Archive
An opinion article aims to provide evidence that SP could be the possible factor for initiating the cytokine storm during severe SARS-CoV-2 infection.
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.
Ten years ago, a landmark clinical trial in Canada demonstrated the unequivocal effectiveness of brain surgeries for treating uncontrolled epilepsy, but since then the procedure has not been widely adopted-in fact, it is dramatically underutilized according to a new study from the University of California, San Francisco (UCSF).
› Verified 5 days ago
| Entity Name | Thedacare Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376656959 PECOS PAC ID: 1759294887 Enrollment ID: O20031106000088 |
News Archive
An opinion article aims to provide evidence that SP could be the possible factor for initiating the cytokine storm during severe SARS-CoV-2 infection.
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.
Ten years ago, a landmark clinical trial in Canada demonstrated the unequivocal effectiveness of brain surgeries for treating uncontrolled epilepsy, but since then the procedure has not been widely adopted-in fact, it is dramatically underutilized according to a new study from the University of California, San Francisco (UCSF).
› Verified 5 days ago
| Entity Name | Thedacare Regional Medical Center - Appleton, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902832306 PECOS PAC ID: 2163319039 Enrollment ID: O20040304000064 |
News Archive
An opinion article aims to provide evidence that SP could be the possible factor for initiating the cytokine storm during severe SARS-CoV-2 infection.
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.
Ten years ago, a landmark clinical trial in Canada demonstrated the unequivocal effectiveness of brain surgeries for treating uncontrolled epilepsy, but since then the procedure has not been widely adopted-in fact, it is dramatically underutilized according to a new study from the University of California, San Francisco (UCSF).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Amanda Kay Douma, APNP 420 E Division St, Fond Du Lac, WI 54935-4560 Ph: () - | Mrs Amanda Kay Douma, APNP 333 N Green Bay Rd Ste B, Neenah, WI 54956-1954 Ph: (920) 454-7130 |
News Archive
An opinion article aims to provide evidence that SP could be the possible factor for initiating the cytokine storm during severe SARS-CoV-2 infection.
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.
Ten years ago, a landmark clinical trial in Canada demonstrated the unequivocal effectiveness of brain surgeries for treating uncontrolled epilepsy, but since then the procedure has not been widely adopted-in fact, it is dramatically underutilized according to a new study from the University of California, San Francisco (UCSF).
› Verified 5 days ago
Lori A. Franck, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 100 Theda Clark Medical Plz Ste 400, Neenah, WI 54956 Phone: 920-725-4527 | |
Mrs. Bonnie B Hoersch, APNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 130 2nd St, Neenah, WI 54956 Phone: 920-729-2738 Fax: 920-729-3023 | |
Pamela Macwilliams, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 130 2nd St Ste 197, Neenah, WI 54956 Phone: 920-729-2030 | |
Ellen Beltz, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 130 2nd St, Neenah, WI 54956 Phone: 920-729-2738 | |
Marie K Dziewit, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 100 Theda Clark Medical Plz Ste 400, Neenah, WI 54956 Phone: 920-725-4527 Fax: 920-729-2378 | |
Brittany R Burg, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 130 2nd St, Neenah, WI 54956 Phone: 920-729-2030 Fax: 920-729-9384 |